Due to this fact, it is significant to note that although there have been studies conducted on the role of Gal-1 in cardiovascular diseases, especially HF, there are currently no clinical trials to confirm its prognostic value, molecular effects, and therapeutic properties. This evidence concerns the gene LGALS1 and cardiovascular disorder.